Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients

1997 ◽  
Vol 65 (3) ◽  
pp. 499-505 ◽  
Author(s):  
M. Bruzzone ◽  
A. Rubagotti ◽  
A. Gadducci ◽  
E. Catsafados ◽  
G. Foglia ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Advanced Ovarian Cancer ◽  
Prospective Randomized Trial ◽  
Interferon Α ◽  
Second Look ◽  
Minimal Residual

The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy

1990 ◽  
Vol 39 (2) ◽  
pp. 150-154 ◽  
Author(s):  
Giorgio Bolis ◽  
Flavia Zanaboni ◽  
Paolo Vanoli ◽  
Antonio Russo ◽  
Massimo Franchi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Advanced Ovarian Cancer ◽  
The Impact ◽  
Minimal Residual

Intraperitoneal (ip) Cisplatin-Mitoxantrone-Interferon-α2b in Ovarian Cancer Patients with Minimal Residual Disease

1993 ◽  
Vol 50 (1) ◽  
pp. 60-67 ◽  
Author(s):  
G. Frasci ◽  
A. Tortoriello ◽  
G. Facchini ◽  
S. Conforti ◽  
A. Cardone ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Interferon Α2b ◽  
Minimal Residual

scholarly journals Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study

2005 ◽  
Vol 23 (4) ◽  
pp. 751-758 ◽  
Author(s):  
Angiolo Gadducci ◽  
Enrico Sartori ◽  
Fabio Landoni ◽  
Paolo Zola ◽  
Tiziano Maggino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Residual Disease ◽  
Advanced Ovarian Cancer ◽  
Complete Response ◽  
Time Interval ◽  
Primary Surgery ◽  
Second Look ◽  
Platinum Based Chemotherapy

Purpose To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients. Patients and Methods The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range, 6 to 109 months). Results The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a pathologic complete response at second-look surgery and 98 obtained a clinical complete response but were not submitted to second-look surgery. Taking into consideration the best assessed response, a complete (either clinical or pathologic) response was found in 200 patients. Residual disease (≤ 1 v > 1 cm; P < .0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival. Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days. Conclusion The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.

1272 Ovarian cancer patients with minimal residual disease: TPA, CA-125 and TATI sensitivity

1995 ◽  
Vol 31 ◽  
pp. S265
Author(s):  
Z. Stanojević ◽  
M. Milutinović ◽  
N. Potic Zećevic ◽  
S. Radić ◽  
S. Filipović
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Ca 125 ◽  
Minimal Residual
Sign in / Sign up

Export Citation Format

Share Document